Mariani-Kurkdjian P, Doit C, Bingen E
CNR associé E. coli-Shigella, Service de Microbiologie, Université Paris-Diderot, Hôpital Robert Debré, 48, boulevard Sérurier, 75935 Paris cedex 19, France.
Arch Pediatr. 2012 Nov;19 Suppl 3:S93-6. doi: 10.1016/S0929-693X(12)71280-0.
Extended-spectrum beta-lactamase (ESBLs) are defined as ß-lactamase able to hydrolyze all penicillins and cephalosporins with the exception of cephamycins (cefotixin, cefotetan), moxalactam and carbapenems and are encoded by mobile genes. The most frequently encountered ESBLs belong to the CTX-M, SHV, and TEM families. ESBLs were found first in Klebsiella pneumonia and then predominantly in E. coli. The incidence of patients with ESBLs E. coli increase since 2000 in Robert Debré Hospital in Paris. They were mainly implicated in urinary tract infections and less frequently in other infections such as materno-foetal infections or neonatal meningitis. An increase of consumption of carbapenems may lead to spread of carbapenem resistant organisms. Thus alternative to carbapenems for treatment of ESBL producers are needed.
超广谱β-内酰胺酶(ESBLs)被定义为能够水解除头霉素(头孢替坦、头孢西丁)、莫西沙星和碳青霉烯类以外的所有青霉素和头孢菌素的β-内酰胺酶,由移动基因编码。最常见的ESBLs属于CTX-M、SHV和TEM家族。ESBLs首先在肺炎克雷伯菌中被发现,然后主要在大肠杆菌中被发现。自2000年以来,巴黎罗伯特·德布雷医院产ESBLs大肠杆菌患者的发病率有所增加。它们主要与尿路感染有关,较少与其他感染有关,如母婴感染或新生儿脑膜炎。碳青霉烯类药物使用量的增加可能导致耐碳青霉烯类微生物的传播。因此,需要有替代碳青霉烯类药物来治疗产ESBLs的细菌。